MedTrace Logo

Replication of the IMPACT COPD Trial in Healthcare Claims Data

NCT05062304 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 17281

Last updated 2023-07-27

No results posted yet for this study

Summary

Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.

Conditions

Interventions

DRUG

Fluticasone Furoate-Vilanterol Trifenatate

Fluticasone Furoate-Vilanterol Trifenatate dispensing claim is used as the reference group.

DRUG

Furoate-umeclidinium-vilanterol

Furoate-umeclidinium-vilanterol dispensing claim is used as the exposure group.

Sponsors & Collaborators

  • Brigham and Women's Hospital

    lead OTHER

Principal Investigators

  • Shirley Wang, PhD, ScM · Brigham and Women's Hospital

Eligibility

Min Age
40 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-13
Primary Completion
2021-07-22
Completion
2021-07-22
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05062304 on ClinicalTrials.gov